140 related articles for article (PubMed ID: 31868861)
61. Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa.
Lin HY; Huang YH; Liao HC; Liu HC; Hsu TR; Shen CI; Li ST; Li CF; Lee LH; Lee PC; Huang CK; Chiang CC; Lin SP; Niu DM
J Chin Med Assoc; 2014 Apr; 77(4):190-7. PubMed ID: 24388678
[TBL] [Abstract][Full Text] [Related]
62. Liquid chromatography-tandem mass spectrometry quantification of globotriaosylceramide in plasma for long-term monitoring of Fabry patients treated with enzyme replacement therapy.
Roddy TP; Nelson BC; Sung CC; Araghi S; Wilkens D; Zhang XK; Thomas JJ; Richards SM
Clin Chem; 2005 Jan; 51(1):237-40. PubMed ID: 15514097
[No Abstract] [Full Text] [Related]
63. Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy was underpowered.
Ortiz A; Sanchez-Niño MD
Drug Des Devel Ther; 2015; 9():5873-4. PubMed ID: 26586938
[No Abstract] [Full Text] [Related]
64. Enzyme replacement therapy in two Japanese siblings with Fabry disease, and its effectiveness on angiokeratoma and neuropathic pain.
Furujo M; Kubo T; Kobayashi M; Ohashi T
Mol Genet Metab; 2013 Nov; 110(3):405-10. PubMed ID: 23906479
[TBL] [Abstract][Full Text] [Related]
65. Enzyme replacement in the treatment of Fabry's disease. Is there a point-of-no-return?
del Toro N; Milán JA; Palma A
Nephrol Dial Transplant; 2004 Apr; 19(4):1018. PubMed ID: 15031378
[No Abstract] [Full Text] [Related]
66. Authors’ reply.
Goláň L; Chang P
Drug Des Devel Ther; 2015; 9():5875. PubMed ID: 26918251
[No Abstract] [Full Text] [Related]
67. Ultrastructural Evidence of Glycosphingolipid Degradation After Enzyme Replacement Therapy in Patients With Fabry Disease.
Onoue K; Takemura G; Nakano T; Miyazaki N; Tsujimoto A; Watanabe T; Okada H; Kanamori H; Sugiura J; Kanaoka K; Ishihara S; Horii M; Akai Y; Sakaguchi Y; Saito Y
Circ J; 2019 Sep; 83(10):2081. PubMed ID: 30930427
[No Abstract] [Full Text] [Related]
68. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease.
Germain DP; Charrow J; Desnick RJ; Guffon N; Kempf J; Lachmann RH; Lemay R; Linthorst GE; Packman S; Scott CR; Waldek S; Warnock DG; Weinreb NJ; Wilcox WR
J Med Genet; 2015 May; 52(5):353-8. PubMed ID: 25795794
[TBL] [Abstract][Full Text] [Related]
69. Successful desensitization with agalsidase alfa in 2 brothers with Fabry disease.
Aydin O; Kasapkara CS; Celik GE
J Investig Allergol Clin Immunol; 2013; 23(5):367-8. PubMed ID: 24260986
[No Abstract] [Full Text] [Related]
70. Enzyme replacement therapy and Fabry nephropathy.
Warnock DG; Daina E; Remuzzi G; West M
Clin J Am Soc Nephrol; 2010 Feb; 5(2):371-8. PubMed ID: 20007680
[TBL] [Abstract][Full Text] [Related]
71. Fabry disease in children and response to enzyme replacement therapy: results from the Fabry Outcome Survey.
Ramaswami U; Parini R; Pintos-Morell G; Kalkum G; Kampmann C; Beck M;
Clin Genet; 2012 May; 81(5):485-90. PubMed ID: 21457233
[TBL] [Abstract][Full Text] [Related]
72. Symptoms and Quality of Life in Patients with Fabry Disease: Results from an International Patient Survey.
Morand O; Johnson J; Walter J; Atkinson L; Kline G; Frey A; Politei J; Schiffmann R
Adv Ther; 2019 Oct; 36(10):2866-2880. PubMed ID: 31435831
[TBL] [Abstract][Full Text] [Related]
73. Successful desensitization to agalsidase beta after anaphylaxis.
Talreja N; Butt A; Valle RL; Fox RW; Lockey RF
Ann Allergy Asthma Immunol; 2014 Jan; 112(1):71-2. PubMed ID: 24331397
[No Abstract] [Full Text] [Related]
74. Anderson-Fabry disease: enzyme replacement therapy.
Leon-Mateos A; Fernández-Redondo V; Beiras A; Toribio J
Acta Derm Venereol; 2004; 84(1):88-9. PubMed ID: 15040494
[No Abstract] [Full Text] [Related]
75. [Renal involvement in Fabry's disease: diagnosis, follow-up and enzyme replacement therapy].
Mignani R; Feriozzi S; Carraro G; Martinelli F; Cianciaruso B
G Ital Nefrol; 2009; 26(5):577-84. PubMed ID: 19802803
[TBL] [Abstract][Full Text] [Related]
76. An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy.
Goker-Alpan O; Longo N; McDonald M; Shankar SP; Schiffmann R; Chang P; Shen Y; Pano A
Drug Des Devel Ther; 2016; 10():1771-81. PubMed ID: 27307708
[TBL] [Abstract][Full Text] [Related]
77. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
Tsuboi K; Yamamoto H
BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
[TBL] [Abstract][Full Text] [Related]
78. Amelioration of serum 8-OHdG level by enzyme replacement therapy in patients with Fabry cardiomyopathy.
Chen KH; Chou YC; Hsiao CY; Chien Y; Wang KL; Lai YH; Chang YL; Niu DM; Yu WC
Biochem Biophys Res Commun; 2017 Apr; 486(2):293-299. PubMed ID: 28300554
[TBL] [Abstract][Full Text] [Related]
79. Analysis of placental tissue in Fabry disease with and without enzyme replacement therapy.
Bouwman MG; Hollak CE; van den Bergh Weerman MA; Wijburg FA; Linthorst GE
Placenta; 2010 Apr; 31(4):344-6. PubMed ID: 20189642
[TBL] [Abstract][Full Text] [Related]
80. Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy.
Mignani R; Feriozzi S; Schaefer RM; Breunig F; Oliveira JP; Ruggenenti P; Sunder-Plassmann G
Clin J Am Soc Nephrol; 2010 Feb; 5(2):379-85. PubMed ID: 20056752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
